Eli Lilly's (LLY) Oral GLP-1, Orforglipron, delivered superior blood sugar control and weight loss compared to oral Semaglutide in head-to-head Type 2 Diabetes trial, published in the Lancet
Importance
Level 1
#ELI LILLY & CO#LLY.US#EQUITIES#EU SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#ELI LILLY AND CO#LLY#US EQUITIES